Chengdu Kangnuoxing Biopharma,inc.
Clinical trials sponsored by Chengdu Kangnuoxing Biopharma,inc., explained in plain language.
-
New drug trial offers hope for painful skin blistering disease
Disease control Not yet recruitingThis study is testing whether an injectable drug called stapokibart can help control moderate to severe bullous pemphigoid, a condition that causes painful, itchy skin blisters. Researchers will compare stapokibart against a placebo (inactive injection) in 200 adults to see if it…
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New SAR treatment safety check begins
Disease control Not yet recruitingThis study aims to check the safety of Stapokibart Injection in adults with SAR. It will enroll 400 participants who are already prescribed this treatment by their doctor. Researchers will carefully track any side effects or reactions people experience while receiving the injecti…
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC